Expression of miRNA-146b-5p in patients with thyroid cancer in combination with Hashimoto's disease and its clinical significance

Li,Ninglei; Liu,Xiaolong; Han,Luzhe; Zhou,Rui; Yan,Jian; Zhao,Guoxiang; Liu,Lixin

doi:10.3892/ol.2019.10173

Expression of miRNA-146b-5p in patients with thyroid cancer in combination with Hashimoto's disease and its clinical significance

Authors:
- Ninglei Li
- Xiaolong Liu
- Luzhe Han
- Rui Zhou
- Jian Yan
- Guoxiang Zhao
- Lixin Liu
View Affiliations

Affiliations: Department of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510000, P.R. China
Published online on: March 20, 2019 https://doi.org/10.3892/ol.2019.10173
Pages: 4871-4876

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression level of microRNA (miRNA)-146b in patients with thyroid carcinoma (TC) in combination with Hashimoto's thyroditis (HT) was evaluated to analyze the clinical significance. Eighty-seven patients who underwent thyroid surgery in The Third Affiliated Hospital of Southern Medical University from March 2010 to February 2013 were enrolled. Of the patients, 37 were diagnosed with TC (group A), and 50 were diagnosed with TC in combination with HT (group B). Forty patients were diagnosed with HT (group C). The expression levels of miRNA-146b-5p in cancer tissue and paracancerous tissue of patients in the two groups were measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Correlation between the miRNA‑146b-5p levels and the clinicopathological characteristics of patients with combined TC and HT were evaluated. According to the expression of miRNA-146b-5p, patients in group B were separated into the high and low expression groups to observe the five-year cancer recurrence rate. There was no significant difference in miRNA-146b-5p expression between the papillary carcinoma group, the follicular carcinoma group and the medullary carcinoma group (P>0.05). The miRNA-146b-5p expression in the lesion tissue of group B was significantly higher than that of groups A and C, while the miRNA-146b-5p expression in the lesion tissue of group A was significantly higher than that of group C (P<0.05), and the lesion tissue of the three groups was higher than that of the corresponding parastatal tissue (P<0.05). The miRNA-146b-5p expression level was associated with tumor size, lymph node metastasis and TNM stage (P<0.05), while not associated with sex, age, lesion multiplicity, smoking history, diabetes history and patho- logical type in group B (P>0.05). The non‑recurrence rate of group B high expression subgroup was lower than that of group B low expression subgroup (P=0.045). High expression of miRNA-146b-5p was found in the cancer tissues of patients with combined TC and HT. The expression level of miRNA-146b-5p was associated with tumor size, lymph node metastasis and TNM stage. It is a potential prognostic indicator for patients with combined TC and HT.

View Figures

View References

1	Torimoto K, Okada Y, Nakayamada S, Kubo S and Tanaka Y: Anti-PD-1 antibody therapy induces Hashimoto's disease with an increase in peripheral blood follicular helper T cells. Thyroid. 27:1335–1336. 2017. View Article : Google Scholar : PubMed/NCBI
2	Zaletel K and Gaberšček S: Hashimoto's thyroiditis: From genes to the disease. Curr Genomics. 12:576–588. 2011. View Article : Google Scholar : PubMed/NCBI
3	Sendt W, Rippe V, Flor I, Drieschner N and Bullerdiek J: Monosomy and ring chromosome 13 in a thyroid nodular goiter - do we underestimate its relevance in benign thyroid lesions? Cancer Genet. 205:128–130. 2012. View Article : Google Scholar : PubMed/NCBI
4	Song E, Jeon MJ, Park S, Kim M, Oh HS, Song DE, Kim WG, Kim WB, Shong YK and Kim TY: Influence of coexistent Hashimoto's thyroiditis on the extent of cervical lymph node dissection and prognosis in papillary thyroid carcinoma. Clin Endocrinol (Oxf). 88:123–128. 2018. View Article : Google Scholar : PubMed/NCBI
5	Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, et al: American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma: Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 25:567–610. 2015. View Article : Google Scholar : PubMed/NCBI
6	La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F and Negri E: Thyroid cancer mortality and incidence: A global overview. Int J Cancer. 136:2187–2195. 2015. View Article : Google Scholar : PubMed/NCBI
7	Zhao J, Xu C, Yao J, Yu C, Liao L and Dong J: Statins and thyroid carcinoma: A meta-analysis. Cell Physiol Biochem. 47:1422–1431. 2018. View Article : Google Scholar : PubMed/NCBI
8	Fallahi P, Ferrari SM, Camastra S, Politti U, Ruffilli I, Vita R, Navarra G, Benvenga S and Antonelli A: TSH normalization in bariatric surgery patients after the switch from L-thyroxine in tablet to an oral liquid formulation. Obes Surg. 27:78–82. 2017. View Article : Google Scholar : PubMed/NCBI
9	Wu ZG, Yan XQ, Su RS, Ma ZS, Xie BJ and Cao FL: How many contralateral carcinomas in patients with unilateral papillary thyroid microcarcinoma are preoperatively misdiagnosed as benign? World J Surg. 41:129–135. 2017. View Article : Google Scholar : PubMed/NCBI
10	Trzybulska D, Bobjer J, Giwercman A and Tsatsanis C: Serum microRNAs in male subfertility-biomarkers and a potential pathogenetic link to metabolic syndrome. J Assist Reprod Genet. 34:1277–1282. 2017. View Article : Google Scholar : PubMed/NCBI
11	Kasinski AL, Kelnar K, Stahlhut C, Orellana E, Zhao J, Shimer E, Dysart S, Chen X, Bader AG and Slack FJ: A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. 34:3547–3555. 2015. View Article : Google Scholar : PubMed/NCBI
12	Lima CR, Geraldo MV, Fuziwara CS, Kimura ET and Santos MF: MiRNA-146b-5p upregulates migration and invasion of different papillary thyroid carcinoma cells. BMC Cancer. 16:1082016. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Kagawa T, Watanabe M, Inoue N, Otsu H, Saeki M, Katsumata Y, Takuse Y and Iwatani Y: Increases of microRNA let-7e in peripheral blood mononuclear cells in Hashimoto's disease. Endocr J. 63:375–380. 2016. View Article : Google Scholar : PubMed/NCBI
15	Girardi FM, Barra MB and Zettler CG: Papillary thyroid carcinoma: Does the association with Hashimoto's thyroiditis affect the clinicopathological characteristics of the disease? Braz J Otorhinolaryngol. 81:283–287. 2015. View Article : Google Scholar : PubMed/NCBI
16	Lang BH, Shek TW, Chan AO, Lo CY and Wan KY: Significance of size of persistent/recurrent central nodal disease on surgical morbidity and response to therapy in reoperative neck dissection for papillary thyroid carcinoma. Thyroid. 27:67–73. 2017. View Article : Google Scholar : PubMed/NCBI
17	Lu Z, Zhang Y, Feng D, Sheng J, Yang W and Liu B: Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma. Oncotarget. 8:45784–45792. 2017.PubMed/NCBI
18	Hay ID, Johnson TR, Thompson GB, Sebo TJ and Reinalda MS: Minimal extrathyroid extension in papillary thyroid carcinoma does not result in increased rates of either cause-specific mortality or postoperative tumor recurrence. Surgery. 159:11–19. 2016. View Article : Google Scholar : PubMed/NCBI
19	Schwarzenbach H, Nishida N, Calin GA and Pantel K: Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 11:145–156. 2014. View Article : Google Scholar : PubMed/NCBI
20	Hill M and Tran N: MicroRNAs regulating microRNAs in cancer. Trends Cancer. 4:465–468. 2018. View Article : Google Scholar : PubMed/NCBI
21	Nakasa T, Miyaki S, Okubo A, Hashimoto M, Nishida K, Ochi M and Asahara H: Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 58:1284–1292. 2008. View Article : Google Scholar : PubMed/NCBI
22	Chou CK, Chi SY, Huang CH, Chou FF, Huang CC, Liu RT and Kang HY: IRAK1, a target of miR-146b, reduces cell aggressiveness of human papillary thyroid carcinoma. J Clin Endocrinol Metab. 101:4357–4366. 2016. View Article : Google Scholar : PubMed/NCBI
23	Chou CK, Yang KD, Chou FF, Huang CC, Lan YW, Lee YF, Kang HY and Liu RT: Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab. 98:E196–E205. 2013. View Article : Google Scholar : PubMed/NCBI
24	Sun M, Fang S, Li W, Li C, Wang L, Wang F and Wang Y: Associations of miR-146a and miR-146b expression and clinical characteristics in papillary thyroid carcinoma. Cancer Biomark. 15:33–40. 2015. View Article : Google Scholar : PubMed/NCBI
25	Taganov KD, Boldin MP, Chang KJ and Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 103:12481–12486. 2006. View Article : Google Scholar : PubMed/NCBI
26	Lee YS, Lim YS, Lee JC, Wang SG, Park HY, Kim SY and Lee BJ: Differential expression levels of plasma-derived miR-146b and miR-155 in papillary thyroid cancer. Oral Oncol. 51:77–83. 2015. View Article : Google Scholar : PubMed/NCBI